Takeda UK Ltd: NICE recommends LIVTENCITY? (maribavir) for t

Takeda UK Ltd. is pleased to announce that NICE has recommended the use of LIVTENCITY? (maribavir) as a twice daily oral treatment for adult patients with post-transplant cytomegalovirus (CMV)

Related Keywords

Australia , Japan , Canada , United Kingdom , London , City Of , British , Rachel Miller , El Chaer , Anthony Nolan , Peter Wheatley , Mark Harber , Simon Meadowcroft , Maribavir Sm , Drug Administration , Prnewswire Takeda United Kingdom Ltd , British Society Of Blood , Regulatory Agency , Takeda Pharmaceutical Company , National Institute For Health , Takeda Pharmaceutical Company Limited , Takeda United Kingdom Ltd , Takeda United Kingdom , Transplanted Organ , National Institute , Care Excellence , Final Appraisal Determination , Marketing Authorisation , Lead Nurse , Consultant Nephrologist , Royal Free London , Country Medical Director , Market Access , Pricing Director , United Kingdom Summary , Product Characteristics , Marketing Authorization , European Economic Area , Pharmaceutical Company Limited , Plasma Derived Therapies , Accessed December , Health Utilization Cost , Resistant Cytomegalovirus Infections , Solid Organ Transplant Recipients , Clinical Infectious Diseases , Organ Donation , Activity Report , Accessed November , British Society , Marrow Transplantation , Cellular Therapies , Takeda , Ice , Ecommends , Ivtencity , Maribavir , Treatment , Adults , Most , Transplant , Cytomegalovirus , Refractory , Without , Resistance , Rior , Therapies ,